The Pakistan-China Pharmaceutical & Healthcare B2B Investment Conference 2026 will be held on 17-18 July 2026 in Islamabad under the collaborative leadership of the Special Investment Facilitation Council (SIFC), the Ministry of National Health Services, Regulations and Coordination (NHSR&C), and the Drug Regulatory Authority of Pakistan (DRAP).
As per a statement, the conference will represent a significant initiative to deepen Pakistan-China economic cooperation by promoting investment, innovation, and strategic partnerships in the pharmaceutical, healthcare, and biotechnology sectors.
“It reflects SIFC’s continued commitment to facilitating foreign direct investment and creating an enabling environment for sustainable industrial growth,” as per a statement.
The conference is designed as a premier business-to-business (B2B) platform and will bring together leading Pakistani pharmaceutical, healthcare, and biotechnology companies with Chinese investors, manufacturers, technology providers, and industry leaders.
The statement said that the event will provide participants with valuable opportunities to establish commercial partnerships, explore investment prospects, and strengthen cross-border business collaboration.
“Delegates will engage in structured B2B meetings, networking sessions, and investment discussions aimed at fostering joint ventures, technology transfer, contract manufacturing, research collaboration, and local production partnerships.
The conference is expected to facilitate meaningful business engagements that support the modernisation of Pakistan’s healthcare ecosystem while enhancing the competitiveness of its pharmaceutical industry, as per the press release.
The Pakistan-China Pharmaceutical & Healthcare B2B Investment Conference 2026 is expected to further reinforce the longstanding strategic partnership between Pakistan and China by encouraging long-term industrial collaboration and unlocking new avenues of investment that contribute to sustainable economic development and shared prosperity.